ERBB2 and breast cancer: Adjuvant postoperative RT within 2–4 months post surgery, for high-risk BC patients (inflammatory BC, lymph node positive, TNBC or HER2+, residual disease after neoadjuvant therapy, young age [<40 years]) [28,50,77].